Humoral COVID-19 vaccine response in patients with NMOSD/MOGAD during anti-IL-6 receptor therapy compared to other immunotherapies.
COVID-19
MOGAD
SARS-CoV-2
Vaccination
satralizumab
tocilizumab
vaccine response
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
medline:
12
5
2023
pubmed:
8
2
2023
entrez:
7
2
2023
Statut:
ppublish
Résumé
Data on the humoral vaccine response in patients on anti-interleukin-6 (IL-6) receptor therapy remain scarce. The main objective of our study was to investigate the humoral response after vaccination against SARS-CoV-2 in neuromyelitis optica spectrum disorder (NMOSD)/myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) patients treated with anti-IL-6 receptor therapy. Secondarily, we analyzed relapse activity timely associated with vaccination. In this retrospective cross-sectional multicenter study, we included 15 healthy controls and 48 adult NMOSD/MOGAD patients without previous COVID-19 infection. SARS-CoV-2 spike protein antibody titers during anti-IL-6 receptor therapy were compared to anti-CD20 antibody therapy, oral immunosuppressants, and to nonimmunosuppressed individuals. We observed 100% seroconversion in the anti-IL-6 receptor treatment group. Titers of SARS-CoV-2 spike protein antibodies were lower compared to healthy controls (720 vs 2500 binding antibody units (BAU)/mL, Despite being lower than in healthy controls, the humoral vaccine response during anti-IL-6 receptor therapy was evident in all patients and substantially stronger compared to anti-CD20 treatment. No relevant disease activity occurred after mRNA vaccination against SARS-CoV-2.
Sections du résumé
BACKGROUND
Data on the humoral vaccine response in patients on anti-interleukin-6 (IL-6) receptor therapy remain scarce.
OBJECTIVE
The main objective of our study was to investigate the humoral response after vaccination against SARS-CoV-2 in neuromyelitis optica spectrum disorder (NMOSD)/myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) patients treated with anti-IL-6 receptor therapy. Secondarily, we analyzed relapse activity timely associated with vaccination.
METHODS
In this retrospective cross-sectional multicenter study, we included 15 healthy controls and 48 adult NMOSD/MOGAD patients without previous COVID-19 infection. SARS-CoV-2 spike protein antibody titers during anti-IL-6 receptor therapy were compared to anti-CD20 antibody therapy, oral immunosuppressants, and to nonimmunosuppressed individuals.
RESULTS
We observed 100% seroconversion in the anti-IL-6 receptor treatment group. Titers of SARS-CoV-2 spike protein antibodies were lower compared to healthy controls (720 vs 2500 binding antibody units (BAU)/mL,
CONCLUSIONS
Despite being lower than in healthy controls, the humoral vaccine response during anti-IL-6 receptor therapy was evident in all patients and substantially stronger compared to anti-CD20 treatment. No relevant disease activity occurred after mRNA vaccination against SARS-CoV-2.
Identifiants
pubmed: 36748649
doi: 10.1177/13524585221151124
pmc: PMC9908518
doi:
Substances chimiques
spike protein, SARS-CoV-2
0
COVID-19 Vaccines
0
Antibodies
0
Immunosuppressive Agents
0
RNA, Messenger
0
Antibodies, Viral
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
757-761Références
J Neurol. 2022 May;269(5):2286-2292
pubmed: 35235002
Int J Infect Dis. 2022 Dec;125:195-208
pubmed: 36328289
Neurology. 2015 Jul 14;85(2):177-89
pubmed: 26092914
Nat Med. 2021 Nov;27(11):1990-2001
pubmed: 34522051
N Engl J Med. 2019 Nov 28;381(22):2114-2124
pubmed: 31774956
J Neuroinflammation. 2018 May 3;15(1):134
pubmed: 29724224
Mult Scler Relat Disord. 2022 Jan;57:103321
pubmed: 35158439
Mod Rheumatol. 2014 May;24(3):511-6
pubmed: 24252023
Cold Spring Harb Perspect Biol. 2014 Sep 04;6(10):a016295
pubmed: 25190079